A Phase 2 interventional study of Standard lymphodepletion regimen in Stiff-Person Syndrome and SPS, sponsored by Kyverna Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Kyverna Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.
Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 10th registered.
20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.
Browse Stiff-Person Syndrome studies →4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:
Thomas Jefferson University · Sites in United States
Ages 25–80
Kyverna Therapeutics · Sites in United States
Ages 18+
Adicet Therapeutics · Sites in United States
Ages 18–80
University of South Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 2
First in 1996; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is close to the median of 25 across 12 interventional studies indexed under Stiff-Person Syndrome.
Median enrollment 24 across the 10 interventional studies, 55 across the 2 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
Kyverna Therapeutics is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Kyverna Therapeutics has 2 studies filed under Stiff-Person Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Stiff-Person Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06528392University of South FloridaEfgartigimod for Stiff Person Syndrome (ESPS) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Stiff-Person Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
Stiff person syndrome (SPS) is a rare progressive immune-mediated disorder of the central nervous system (CNS) that is characterized by progressive rigidity and painful spasms of predominantly axial and proximal limb muscles. The condition gradually worsens over time and left untreated, it can lead to permanent disability and in some cases, mortality.
B cells contribute to systemic autoimmunity and development of disease in several ways, most notably via cytokine production, antigen presentation and complement activation (via autoantibody production). In SPS, B cell involvement is supported by the presence of antibodies against glutamic acid decarboxylase (GAD), which is widely expressed within the CNS, catalyzing the conversion of the excitatory neurotransmitter l-glutamate to the inhibitory GABA.
CAR-T therapy such as KYV-101 may be an effective treatment for SPS, by targeting these autoreactive B cells. Using chimeric antigen receptor (CAR) T-cell technology, engineered T cells with receptors are designed to recognize and eliminate B cells, including those that produce GAD autoantibodies. This approach aims to intervene at the root of the autoimmune response, offering a precise and potentially transformative treatment for SPS. CAR-T cell therapy holds promise as a targeted and effective intervention, addressing the autoimmune component directly and potentially halting disease progression.
Key Inclusion Criteria:
Subject must have been diagnosed SPS per the following criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing with KYV-101 CAR T cells
Biological: Standard lymphodepletion regimen
Standard lymphodepletion regimen
Also known as: Cyclophosphamide, Fludarabine
To evaluate efficacy of KYV-101
Change in the Timed 25-Foot Walk (T25-FW) from baseline
Time frame: Up to 12 months
To evaluate the safety of KYV-101
Incidence of adverse events and laboratory abnormalities
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
Change in Modified Rankin Scale from baseline Modified Rankin Scale: Scoring is from 0 (no symptoms) to 6 (death). A higher score indicates a worse outcome.
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
Change in the scores of the distribution-of-stiffness index from baseline. Distribution of Stiffness Index: Scoring is from 0 to 6. A higher score indicates a worse outcome.
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
Change in Hauser Ambulation Index. Hauser Ambulation Index: Scoring is from 0 to 9. A higher score indicates a worse outcome.
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
Change in Heightened sensitivity scale. Heightened Sensitivity Scale: Scoring is from 0 to 7. A higher score indicates a worse outcome.
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
6-minute walk test
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
Change in anti-GAD-65 antibody levels
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
Change in anti-glycine receptor antibodies
Time frame: Up to 12 months
To evaluate efficacy of KYV-101
36-Short form survey (SF-36). The SF-36 has eight scaled scores. Scores range from 0 - 100 with lower scores equating to more disability and higher scores equating to less disability.
Time frame: Up to 12 months
To characterize the pharmacokinetics (PK)
Levels of KYV-101 CAR-positive T cells in the blood
Time frame: Up to 12 months
To evaluate the immunogenicity (humoral response) of KYV-101
Percentage of participants who develop anti-KYV-101 antibodies by immunoassays
Time frame: Up to 12 months
To characterize the pharmacodynamics (PD)
Levels of systemic cytokine concentrations in serum
Time frame: Up to 12 months
To characterize the pharmacodynamics (PD)
Levels of B cells in the blood
Time frame: Up to 12 months
Plan to share: No
Ran from Sep 2024 to primary completion in Jun 2026, 21 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunosuppressive Agents
Kyverna Therapeutics